Blood Screening Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030

Description

Persistence Market Research has conducted a thorough analysis of the Blood Screening Market, providing a comprehensive report detailing its global landscape. This in-depth publication offers valuable insights into the market's dynamics, trends, opportunities, and challenges, providing a comprehensive overview of its structure. Backed by exclusive data and statistics, the research predicts the anticipated growth trajectory of the Blood Screening Market spanning from 2023 to 2030.

The Blood Screening market is anticipated to grow at a compound annual growth rate (CAGR) of 8.5%, resulting in a rise from US$2.22 billion in 2023 to US$3.94 billion by the conclusion of 2030.

Key Insights:

Blood Screening Market Size (2023E): US$2.22 Bn
Projected Market Value (2030F): US$3.94 Bn
Global Market Growth Rate (CAGR 2023 to 2030): 8.5%
Historical Market Growth Rate (CAGR 2018 to 2022):7.2%
Revenue Share of Top Four Countries (2022E):45%

Blood Screening Market - Report Scope

Blood screening involves the systematic analysis of blood samples to detect various pathological conditions, infections, and diseases. It is essential for monitoring diseases, ensuring blood transfusion safety, and promoting preventive healthcare. This diagnostic method is vital for timely identification of blood-borne illnesses like HIV and hepatitis, aiding in public health measures and medical intervention.

The global blood screening market is expanding due to factors such as technological advancements in screening methods, increasing prevalence of infectious diseases, and growing demand for blood transfusions. Stringent regulatory frameworks focusing on blood safety, recognition of early disease detection's importance, and improving healthcare infrastructure in emerging economies further drive market growth. Advancements in screening techniques and the emphasis on personalized medicine also contribute to industry development.

Market Growth Drivers

The global blood screening industry is advancing rapidly through the integration of cutting-edge screening technologies. Innovations such as nucleic acid testing (NAT) and automation have enhanced diagnostic precision and efficiency, shortening detection windows for infections like hepatitis and HIV. Robotics and automation streamline workflows, reduce errors, and increase output, particularly in large-scale diagnostic settings. Emerging technologies like next-generation sequencing (NGS) enable simultaneous analysis of multiple pathogens, improving diagnostic efficacy. Point-of-care testing (POCT) devices offer decentralized screening options, enhancing accessibility, particularly in resource-limited or remote areas. Despite technological advancements, regulatory hurdles pose significant challenges. Stringent compliance mandates necessitate substantial time and resources, delaying the commercialization of innovative screening solutions. Adapting to evolving regulatory standards incurs additional operational costs, highlighting the ongoing complexity of the regulatory environment in the blood screening market.

Market Restraints

The ongoing need for pandemic preparedness presents a significant challenge for the global blood screening market. Emergent infectious diseases like Zika, Ebola, and COVID-19 underscore the vulnerability of blood supplies to new pathogens. Heightened vigilance is required in screening protocols to quickly detect and address emerging threats of transfusion-transmissible infections. Developing and validating specific screening tests for novel diseases adds complexity and time to the screening process, emphasizing the necessity for continual adaptation and preparedness in the face of evolving infectious disease risks.

Opportunities

The global blood screening market benefits from the rising demand for transfusion and blood services worldwide. As populations grow and healthcare systems expand, the need for blood-related medical interventions such as cancer treatments and surgical procedures increases. This heightened demand underscores the importance of blood screening in ensuring an adequate and safe blood supply. Additionally, the growing prevalence of chronic illnesses and aging populations contributes to the increased need for compatible and screened blood units. The expansion of healthcare infrastructure in developing countries further drives demand for streamlined blood screening services, presenting opportunities for market growth. Strengthening healthcare systems globally emphasizes the importance of rigorous blood screening protocols to safeguard transfused blood and minimize transfusion-transmissible infections.

Key Questions Answered in Report:
What are the primary factors driving the growth of the global blood screening market?
What technological advancements are influencing blood screening methods, and how do they impact diagnostic precision and efficiency?
How do regulatory obstacles and compliance mandates affect the commercialization of innovative screening solutions?
What challenges and opportunities does continuous pandemic preparedness present for the blood screening market?
How does the increasing demand for transfusion and blood services on an international scale impact the growth and expansion of the market?

Competitive Intelligence and Business Strategy

Prominent companies in the global blood screening industry, including Abbott Laboratories, Roche Diagnostics, Bio-Rad Laboratories, Grifols, and Ortho Clinical Diagnostics, employ diverse strategies to maintain and expand their market presence. These companies prioritize innovation to develop advanced technologies, such as swift point-of-care testing solutions by Abbott Laboratories and Next Generation Sequencing (NGS) by Roche Diagnostics, enhancing diagnostic speed and accessibility. Partnerships and collaborations, like those between Grifols and Ortho Clinical Diagnostics, bolster technological capacities and product portfolios. Compliance with stringent regulatory standards, exemplified by Abbott Laboratories and Roche Diagnostics, reinforces trust and reliability in the marketplace.

Key Companies Profiled

Abbott
Becton Dickinson and Company
Bio-Rad Laboratories, Inc.
Hoffman-La Roche Ltd.
Grifols, S.A.
Ortho-Clinical Diagnostics, Inc.
Siemens Healthcare GmbH
Thermo Fisher Scientific, Inc.
SOFINA s.a (Biomerieux)
Danaher Corporation (Beckman Coulter)

Blood Screening Market Segmentation

By Technology:

Nucleic Acid Amplification Test (NAT)
ELISA
Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
Next Generation Sequencing
Western Blotting

By Product:

Nucleic Acid Amplification Test (NAT)
ELISA
Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
Next Generation Sequencing
Western Blotting

By Region:

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

Product Code: PMRREP33853

1. Executive Summary

1.1. Global Blood Screening Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Technology Lifecycle Analysis
2.4. Global Blood Screening Market: Value Chain
- 2.4.1. List of Raw Material Supplier
- 2.4.2. List of Manufacturers
- 2.4.3. List of Distributors
- 2.4.4. List of Applications
- 2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
- 2.7.1. Global Sectorial Outlook
- 2.7.2. Global GDP Growth Outlook
- 2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape

3. Global Blood Screening Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

3.1. Key Highlights
- 3.1.1. Market Volume (Units) Projections
- 3.1.2. Market Size and Y-o-Y Growth
- 3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
- 3.2.1. Historical Market Size Analysis, 2013-2016
- 3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Blood Screening Market Outlook: Technology
- 3.3.1. Introduction / Key Findings
- 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Technology, 2018 - 2022
- 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
  - 3.3.3.1. Nucleic Acid Amplification Test (NAT)
  - 3.3.3.2. ELISA
  - 3.3.3.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
  - 3.3.3.4. Next Generation Sequencing
  - 3.3.3.5. Western Blotting
3.4. Market Attractiveness Analysis: Technology
3.5. Global Blood Screening Market Outlook: Product
- 3.5.1. Introduction / Key Findings
- 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Product, 2018 - 2022
- 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
  - 3.5.3.1. Nucleic Acid Amplification Test (NAT)
  - 3.5.3.2. ELISA
  - 3.5.3.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
  - 3.5.3.4. Next Generation Sequencing
  - 3.5.3.5. Western Blotting
3.6. Market Attractiveness Analysis: Product

4. Global Blood Screening Market Outlook: Region

4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. East Asia
- 4.3.4. South Asia and Oceania
- 4.3.5. Latin America
- 4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region

5. North America Global Blood Screening Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 5.3.1. By Country
- 5.3.2. By Technology
- 5.3.3. By Product
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 5.4.1. U.S.
- 5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
- 5.5.1. Nucleic Acid Amplification Test (NAT)
- 5.5.2. ELISA
- 5.5.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
- 5.5.4. Next Generation Sequencing
- 5.5.5. Western Blotting
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 5.6.1. Nucleic Acid Amplification Test (NAT)
- 5.6.2. ELISA
- 5.6.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
- 5.6.4. Next Generation Sequencing
- 5.6.5. Western Blotting
5.7. Market Attractiveness Analysis

6. Europe Global Blood Screening Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 6.3.1. By Country
- 6.3.2. By Technology
- 6.3.3. By Product
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 6.4.1. Germany
- 6.4.2. France
- 6.4.3. U.K.
- 6.4.4. Italy
- 6.4.5. Spain
- 6.4.6. Russia
- 6.4.7. Turkiye
- 6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
- 6.5.1. Nucleic Acid Amplification Test (NAT)
- 6.5.2. ELISA
- 6.5.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
- 6.5.4. Next Generation Sequencing
- 6.5.5. Western Blotting
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 6.6.1. Nucleic Acid Amplification Test (NAT)
- 6.6.2. ELISA
- 6.6.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
- 6.6.4. Next Generation Sequencing
- 6.6.5. Western Blotting
6.7. Market Attractiveness Analysis

7. East Asia Global Blood Screening Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 7.3.1. By Country
- 7.3.2. By Technology
- 7.3.3. By Product
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 7.4.1. China
- 7.4.2. Japan
- 7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
- 7.5.1. Nucleic Acid Amplification Test (NAT)
- 7.5.2. ELISA
- 7.5.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
- 7.5.4. Next Generation Sequencing
- 7.5.5. Western Blotting
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 7.6.1. Nucleic Acid Amplification Test (NAT)
- 7.6.2. ELISA
- 7.6.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
- 7.6.4. Next Generation Sequencing
- 7.6.5. Western Blotting
7.7. Market Attractiveness Analysis

8. South Asia & Oceania Global Blood Screening Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 8.3.1. By Country
- 8.3.2. By Technology
- 8.3.3. By Product
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 8.4.1. India
- 8.4.2. Southeast Asia
- 8.4.3. ANZ
- 8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
- 8.5.1. Nucleic Acid Amplification Test (NAT)
- 8.5.2. ELISA
- 8.5.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
- 8.5.4. Next Generation Sequencing
- 8.5.5. Western Blotting
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 8.6.1. Nucleic Acid Amplification Test (NAT)
- 8.6.2. ELISA
- 8.6.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
- 8.6.4. Next Generation Sequencing
- 8.6.5. Western Blotting
8.7. Market Attractiveness Analysis

9. Latin America Global Blood Screening Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 9.3.1. By Country
- 9.3.2. By Technology
- 9.3.3. By Product
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
- 9.5.1. Nucleic Acid Amplification Test (NAT)
- 9.5.2. ELISA
- 9.5.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
- 9.5.4. Next Generation Sequencing
- 9.5.5. Western Blotting
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 9.6.1. Nucleic Acid Amplification Test (NAT)
- 9.6.2. ELISA
- 9.6.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
- 9.6.4. Next Generation Sequencing
- 9.6.5. Western Blotting
9.7. Market Attractiveness Analysis

10. Middle East & Africa Global Blood Screening Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 10.3.1. By Country
- 10.3.2. By Technology
- 10.3.3. By Product
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 10.4.1. GCC
- 10.4.2. Egypt
- 10.4.3. South Africa
- 10.4.4. Northern Africa
- 10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
- 10.5.1. Nucleic Acid Amplification Test (NAT)
- 10.5.2. ELISA
- 10.5.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
- 10.5.4. Next Generation Sequencing
- 10.5.5. Western Blotting
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 10.6.1. Nucleic Acid Amplification Test (NAT)
- 10.6.2. ELISA
- 10.6.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
- 10.6.4. Next Generation Sequencing
- 10.6.5. Western Blotting
10.7. Market Attractiveness Analysis

11. Competition Landscape

11.1. Market Share Analysis, 2022
11.2. Market Structure
- 11.2.1. Competition Intensity Mapping By Market
- 11.2.2. Competition Analog IC
- 11.2.3. Apparent Technology Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 11.3.1. Abbott
  - 11.3.1.1. Overview
  - 11.3.1.2. Segments and Technology
  - 11.3.1.3. Key Financials
  - 11.3.1.4. Market Developments
  - 11.3.1.5. Market Strategy
- 11.3.2. Becton Dickinson and Company
  - 11.3.2.1. Overview
  - 11.3.2.2. Segments and Technology
  - 11.3.2.3. Key Financials
  - 11.3.2.4. Market Developments
  - 11.3.2.5. Market Strategy
- 11.3.3. Bio-Rad Laboratories, Inc.
  - 11.3.3.1. Overview
  - 11.3.3.2. Segments and Technology
  - 11.3.3.3. Key Financials
  - 11.3.3.4. Market Developments
  - 11.3.3.5. Market Strategy
- 11.3.4. Hoffman-La Roche Ltd.
  - 11.3.4.1. Overview
  - 11.3.4.2. Segments and Technology
  - 11.3.4.3. Key Financials
  - 11.3.4.4. Market Developments
  - 11.3.4.5. Market Strategy
- 11.3.5. Grifols, S.A.
  - 11.3.5.1. Overview
  - 11.3.5.2. Segments and Technology
  - 11.3.5.3. Key Financials
  - 11.3.5.4. Market Developments
  - 11.3.5.5. Market Strategy
- 11.3.6. Ortho-Clinical Diagnostics, Inc.
  - 11.3.6.1. Overview
  - 11.3.6.2. Segments and Technology
  - 11.3.6.3. Key Financials
  - 11.3.6.4. Market Developments
  - 11.3.6.5. Market Strategy
- 11.3.7. Siemens Healthcare GmbH
  - 11.3.7.1. Overview
  - 11.3.7.2. Segments and Technology
  - 11.3.7.3. Key Financials
  - 11.3.7.4. Market Developments
  - 11.3.7.5. Market Strategy
- 11.3.8. Thermo Fisher Scientific, Inc.
  - 11.3.8.1. Overview
  - 11.3.8.2. Segments and Technology
  - 11.3.8.3. Key Financials
  - 11.3.8.4. Market Developments
  - 11.3.8.5. Market Strategy
- 11.3.9. SOFINA s.a (Biomerieux)
  - 11.3.9.1. Overview
  - 11.3.9.2. Segments and Technology
  - 11.3.9.3. Key Financials
  - 11.3.9.4. Market Developments
  - 11.3.9.5. Market Strategy
- 11.3.10. Danaher Corporation (Beckman Coulter)
  - 11.3.10.1. Overview
  - 11.3.10.2. Segments and Technology
  - 11.3.10.3. Key Financials
  - 11.3.10.4. Market Developments
  - 11.3.10.5. Market Strategy

12. Appendix

12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations